Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0ADDII
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Belantamab-Compound (XLII)
|
|||||
| Synonyms |
Belantamab Compound (XLII)
Click to Show/Hide
|
|||||
| Organization |
Orum Therapeutics, Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
1-2
|
|||||
| Structure |
|
|||||
| Antibody Name |
Belantamab
|
Antibody Info | ||||
| Antigen Name |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Therapeutic Target |
Stimulator of interferon genes protein (STING1)
|
Target Info | ||||
| Linker Name |
Belantamab-Compound (XLII) linker
|
|||||